Over the weekend, President Donald Trump signed an executive order directing the Food and Drug Administration to drastically shorten review timelines for certain psychedelic drugs aimed at treating mental illness—slashing the approval window from six to ten months down to just one or two months. The news sent related stocks soaring on Monday. As the policy winds shift abruptly, one question looms large: who is truly positioned to capture the first-mover advantage in this unfolding wave?
The answer points squarely toward biotech companies that already hold the FDA’s “breakthrough therapy” designation and have advanced clinical pipelines. The executive order explicitly prioritizes expedited review for products with this status, effectively carving out a green lane for a select few players.
Topping the list is London-based Compass Pathways (CMPS) . The stock rocketed more than 50% intraday on Monday before closing with a gain of 42.12% , swelling its market capitalization by nearly half in a single session. CEO Kabir Nath remarked that the move “aligns regulatory urgency with patient need.” The market’s exuberant repricing stems from a straightforward calculus: the company’s synthetic psilocybin therapy, COMP360 , is currently being evaluated in two Phase 3 studies for treatment-resistant depression. For biotech firms, faster regulatory reviews translate directly into accelerated commercialization timelines—a shift potent enough to rewrite valuation models overnight.
Close behind is New York-based AtaiBeckley (ATAI) , which soared 32% during intraday trading before settling at a 21.71% gain. Its position is uniquely leveraged: the company is not only a major stakeholder in Compass Pathways but also has three programs of its own in clinical testing—two for treatment-resistant depression and one for social anxiety disorder. This dual-pronged exposure allowed AtaiBeckley to capture a multiplier effect from the policy shift.
The third name is Definium Therapeutics (DFTX) , also headquartered in New York. While its stock movement was more subdued—up more than 4% intraday and closing 2.21% higher—its pipeline warrants attention. The company is evaluating a psychedelic drug for anxiety disorder and major depressive disorder, both with FDA breakthrough therapy status. Given its lower market capitalization, positive clinical readouts could unlock significant upside volatility.
The executive order’s impact extends far beyond mere regulatory acceleration. Its deeper significance lies in the federal government effectively endorsing a sector long shunned by institutional capital.
For years, psychedelic therapies languished under the shadow of Schedule I classification. Despite accumulating scientific evidence, investors balked at what they perceived as an untenable regulatory risk profile. The new order changes that calculus. It not only allocates $50 million to advance private-sector research but also directs the reclassification process for psilocybin and ibogaine. In essence, the White House is underwriting the sector with federal credibility.
As one New York-based hedge fund manager put it: “Previously, you had to apply a punitive regulatory discount to any psychedelic pipeline in your DCF model. The White House just dialed that discount down. Today’s rally is effectively a one-time repricing of that irrational discount.”
Still, the exuberance calls for restraint. No amount of regulatory streamlining can substitute for definitive clinical data. The outcome of Compass’s COMP360 Phase 3 program remains the key variable that will determine the sector’s ceiling. Moreover, psychedelic treatments are not simple pill-based therapies; they require rigorous psychological monitoring and structured therapeutic settings. The commercial scaling challenge is orders of magnitude more complex than that of conventional pharmaceuticals.
For now, Compass Pathways stands as the undisputed frontrunner, buoyed by its advanced pipeline and the day’s largest percentage surge. But in this new era of regulatory accommodation, the final throne belongs only to those who can prove—with hard data—that these compounds can not only alter perception, but genuinely heal.
